Skip to search formSkip to main contentSkip to account menu

brentuximab vedotin 50 MG Injection [Adcetris]

Known as: Adcetris 50 MG Injection, Brentuximab Vedotin 50 mg in 10.5 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ADCETRIS] 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Several peripheral T-cell lymphomas (PTCL) express the tumour necrosis factor (TNF) receptor CD30, conferring cell survival and… 
2017
2017
Antibody Drug Conjugates (ADCs) exploit the specificity of monoclonal antibodies for the targeting of highly potent small… 
2014
2014
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Purpose : Bacterial Transglutaminase (BTG) allows coupling… 
2013
2013
Mit dem Antikörper-Wirkstoff-Konjugat Brentuximab Vedotin (Adcetris®) von Takeda steht seit zwanzig Jahren erstmals wieder eine… 
Review
2012
Review
2012
Brentuximab vedotin is an antibody-drug conjugate (ADC) directed against the tumour necrosis factor (TNF) receptor CD30 which is…